Base de dados : MEDLINE
Pesquisa : C19.642.355 [Categoria DeCS]
Referências encontradas : 12167 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1217 ir para página                         

  1 / 12167 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29177267
[Au] Autor:Mazokopakis E; Papadomanolaki M; Skarakis SN; Tsekouras K
[Ad] Endereço:Department of Internal Medicine, Naval Hospital of Crete, Souda 73 200, Chania, Crete, Greece. emazokopakis@yahoo.gr.
[Ti] Título:Primary and secondary hyperparathyroidism among vitamin D deficient Hashimoto's thyroiditis patients and the need for a parathyroid scan.
[So] Source:Hell J Nucl Med;20(3):258-259, 2017 Sep-Dec.
[Is] ISSN:1790-5427
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:The patients with Hashimoto thyroiditis must be investigated mainly for secondary hyperparathyroidism due to vitamin D deficiency/insufficiency. Parathyroid scintigraphy has no place in the diagnosis of primary, secondary or tertiary hyperparathyroidism or in the decision for surgical treatment. Parathyroid scintigraphy is a useful preoperative technique for the localization of the pathological parathyroid glands.
[Mh] Termos MeSH primário: Doença de Hashimoto/sangue
Doença de Hashimoto/diagnóstico por imagem
Hiperparatireoidismo/sangue
Hiperparatireoidismo/diagnóstico por imagem
Cintilografia/métodos
Deficiência de Vitamina D/sangue
Vitamina D/sangue
[Mh] Termos MeSH secundário: Adulto
Biomarcadores/sangue
Diagnóstico Diferencial
Feminino
Seres Humanos
Masculino
Glândulas Paratireoides/diagnóstico por imagem
Hormônio Paratireóideo/sangue
Reprodutibilidade dos Testes
Sensibilidade e Especificidade
Deficiência de Vitamina D/diagnóstico por imagem
[Pt] Tipo de publicação:LETTER
[Nm] Nome de substância:
0 (Biomarkers); 0 (Parathyroid Hormone); 1406-16-2 (Vitamin D)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE
[do] DOI:10.1967/s002449910613


  2 / 12167 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29341554
[Au] Autor:Tesic-Rajkovic S; Radovanovic-Dinic B; Mitic B; Dinic-Radovic V; Jovanovic M
[Ti] Título:Hyperparathyroidism as a cause of recurrent acute pancreatitis: A case report.
[So] Source:Vojnosanit Pregl;73(11):1064-7, 2016 Nov.
[Is] ISSN:0042-8450
[Cp] País de publicação:Serbia
[La] Idioma:eng
[Ab] Resumo:Introduction: One of the more uncommon etiological factors responsible for the development of acute pancreatitis (AP) is hypercalcemia. Hyperparathyroidism (HPT), as a cause of hypercalcemia, is responsible for 1.5­13% of AP according to a number of studies. A mechanism of the development of AP in hyperparathyroidism is still unclear. Case report: We presented a 47-year-old female patient, who had five episodes of AP in total before the etiological factors were finally determined. The patient had certain comorbidities which were considered to be potential causes of AP. She had chronic renal insufficiency (she was on a regular hemodialysis program), systemic lupus erythematosus and mioma uteri. She used to regularly take an antiepileptic drug (combination of sodium valproate and valproic acid). During the fifth episode of AP, the serum calcium level was for the first time elevated to twice the normal value. Level of parathyroid hormone was several times higher. A static scintigraphy found hyperplasia or hyperfunctional adenoma of the right inferior and superior parathyroid glands. Abdominal multislice computed tomography (MSCT) scan verified the enlargement of the entire pancreas, as well as the presence of heterogeneous structures with diffuse amorphous calcifications. The lytic lesions in the pelvic bones could be seen in both sides. Parathyroidectomy was being postponed by an endocrine surgeon because of the poor overall condition of the patient. In the next period the patient had five more episodes of AP. The condition was significantly contributed by increasingly more frequent and longer episodes of metrorrhagia. Despite all therapeutic measures that were taken, systemic inflammatory response syndrome (SIRS) developed, and fatal outcome occurred. Conclusion: In case of recurrent pancreatitis, hyperparathyroidism is to be considered even if a significant elevation of serum calcium is not present. This is especially the case for patients with chronic renal insufficiency or impaired vitamin D metabolism, who have a higher risk of secondary hyperthyroidism.
[Mh] Termos MeSH primário: Hipercalcemia/etiologia
Hiperparatireoidismo/complicações
Pancreatite/etiologia
[Mh] Termos MeSH secundário: Doença Aguda
Biomarcadores/sangue
Cálcio/sangue
Evolução Fatal
Feminino
Seres Humanos
Hipercalcemia/sangue
Hipercalcemia/diagnóstico
Hipercalcemia/terapia
Hiperparatireoidismo/sangue
Hiperparatireoidismo/diagnóstico por imagem
Hiperparatireoidismo/terapia
Meia-Idade
Tomografia Computadorizada Multidetectores
Pancreatite/sangue
Pancreatite/diagnóstico por imagem
Pancreatite/terapia
Hormônio Paratireóideo/sangue
Cintilografia
Recidiva
Fatores de Risco
Síndrome de Resposta Inflamatória Sistêmica/etiologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (PTH protein, human); 0 (Parathyroid Hormone); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180118
[St] Status:MEDLINE
[do] DOI:10.2298/VSP150210121T


  3 / 12167 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28457397
[Au] Autor:Meng C; Martins P; Frazão J; Pestana M
[Ad] Endereço:Nephrology Department, Centro Hospitalar São João, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal. Electronic address: catarinameng@gmail.com.
[Ti] Título:Parathyroidectomy in Persistent Post-transplantation Hyperparathyroidism - Single-center Experience.
[So] Source:Transplant Proc;49(4):795-798, 2017 May.
[Is] ISSN:1873-2623
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Hyperparathyroidism is a common complication in chronic kidney disease and might persist in up to 25% of patients after transplantation. In this setting, vitamin D analogues further aggravate persistent hypercalcemia and cinacalcet has not been approved for these patients, some of whom will require parathyroidectomy to correct post-transplantation hyperparathyroidism. OBJECTIVES: In this single-center, retrospective study we aimed to analyze the long-term effect of parathyroidectomy on calcium, phosphorus, and parathyroid hormone (PTH) levels and its effect on allograft function in kidney transplantation patients submitted to parathyroidectomy. PATIENTS AND METHODS: Fifteen patients underwent parathyroidectomy between January 2005 and January 2015; median age 54 years old; 8 (53.3%) were receiving cinacalcet at the time of surgery. Pre-parathyroidectomy median values of intact PTH, calcium, and phosphorus were, respectively, 262 pg/mL, 10.8 mg/dL, and 2.4 mg/dL. Surgery consisted of uniglandular parathyroidectomy in 5 (33.3%) patients, biglandular in 4 (26.7%), and subtotal in 6 (40%). There was no surgery-related mortality. RESULTS: Compared with baseline, there was a decrease of PTH (262 pg/mL vs. 106 pg/mL, P = .001), calcium, and phosphorus levels (10.8 mg/dL vs. 10.4 mg/dL, P = .3; 2.4 vs. 2.9 mg/dL, P = .05) 1 year after surgery; with normalization of serum calcium at the end of follow-up (10.8 mg/dL vs. 9.4 mg/dL, P = .04). A decrease in estimated glomerular filtration rate occurred 1 month post-surgery (62.7 mL/m vs. 49.7 mL/m, P = .006) but returned to baseline 1 year after surgery (62.7 mL/m vs. 60.8 mL/m, P = .73). CONCLUSION: Parathyroidectomy appears to be a safe procedure and should be considered in kidney transplantation patients with persistent post-transplantation hyperparathyroidism. Although there was an acute estimated glomerular filtration rate decrease, we observed no long-term deterioration in allograft function.
[Mh] Termos MeSH primário: Aloenxertos/fisiopatologia
Hiperparatireoidismo/cirurgia
Transplante de Rim/efeitos adversos
Paratireoidectomia/métodos
Complicações Pós-Operatórias/cirurgia
[Mh] Termos MeSH secundário: Adulto
Cálcio/sangue
Feminino
Sobrevivência de Enxerto
Seres Humanos
Hiperparatireoidismo/sangue
Hiperparatireoidismo/etiologia
Masculino
Meia-Idade
Hormônio Paratireóideo/sangue
Fósforo/sangue
Complicações Pós-Operatórias/sangue
Complicações Pós-Operatórias/etiologia
Estudos Retrospectivos
Resultado do Tratamento
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Parathyroid Hormone); 27YLU75U4W (Phosphorus); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171218
[Lr] Data última revisão:
171218
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE


  4 / 12167 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29173367
[Au] Autor:Stoopler ET; Aloyouny A; Greenberg MS
[Ad] Endereço:Department of Oral Medicine, University of Pennsylvania School of Dental Medicine, Philadelphia, Pennsylvania. Electronic address: ets@upenn.edu.
[Ti] Título:Uremic Leontiasis Ossea.
[So] Source:Am J Med Sci;354(5):527, 2017 Nov.
[Is] ISSN:1538-2990
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Hiperostose Frontal Interna
Hiperparatireoidismo
Falência Renal Crônica
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
Hiperostose Frontal Interna/complicações
Hiperostose Frontal Interna/diagnóstico por imagem
Hiperostose Frontal Interna/cirurgia
Hiperostose Frontal Interna/urina
Hiperparatireoidismo/complicações
Hiperparatireoidismo/diagnóstico por imagem
Hiperparatireoidismo/cirurgia
Hiperparatireoidismo/urina
Falência Renal Crônica/complicações
Falência Renal Crônica/diagnóstico por imagem
Falência Renal Crônica/cirurgia
Falência Renal Crônica/urina
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171206
[Lr] Data última revisão:
171206
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE


  5 / 12167 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28806048
[Au] Autor:Barstow C
[Ad] Endereço:Womack Army Medical Center, 2817 Reilly Road, Fort Bragg, NC 28310.
[Ti] Título:Electrolytes: Calcium Disorders.
[So] Source:FP Essent;459:29-34, 2017 Aug.
[Is] ISSN:2159-3000
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A normal serum calcium level is 8 to 10 mg/dL. The diagnosis of hypercalcemia (ie, levels 10.5 mg/dL or greater) should be confirmed with an albumin-adjusted or ionized calcium level. The two most common causes of hypercalcemia are hyperparathyroidism and malignancy. Drugs, notably lithium and thiazide diuretics, also can cause hypercalcemia. Patients with severe or symptomatic hypercalcemia should be treated initially with hydration to decrease calcium levels. The evaluation should include a parathyroid hormone (PTH) level. If the PTH level is low, cancer is a likely cause, particularly multiple myeloma, breast cancer, or lymphoma. If the PTH level is normal or elevated, hyperparathyroidism is the likely cause. Symptomatic patients with hyperparathyroidism and patients with certain clinical markers should be considered for surgery. For patients with mild disease, monitoring is an option. Hypocalcemia often is caused by vitamin D deficiency. Symptomatic patients and patients with calcium levels less than 7.6 mg/dL should be treated with intravenous calcium gluconate; concomitant magnesium deficiency should be addressed. There is no evidence that routine calcium and vitamin D supplementation reduces the risk of fractures, but studies have shown that vitamin D supplementation does decrease the number of falls in older adults at risk.
[Mh] Termos MeSH primário: Cálcio/metabolismo
Hipercalcemia/metabolismo
Hipocalcemia/metabolismo
Hormônio Paratireóideo/metabolismo
Vitamina D/metabolismo
[Mh] Termos MeSH secundário: Acidentes por Quedas/prevenção & controle
Antimaníacos/efeitos adversos
Cálcio/uso terapêutico
Gluconato de Cálcio/uso terapêutico
Suplementos Nutricionais
Hidratação
Fraturas Ósseas/prevenção & controle
Seres Humanos
Hipercalcemia/diagnóstico
Hipercalcemia/etiologia
Hipercalcemia/terapia
Hiperparatireoidismo/complicações
Hiperparatireoidismo/cirurgia
Hipocalcemia/diagnóstico
Hipocalcemia/etiologia
Hipocalcemia/terapia
Lítio/efeitos adversos
Neoplasias/complicações
Paratireoidectomia
Inibidores de Simportadores de Cloreto de Sódio/efeitos adversos
Vitamina D/uso terapêutico
Deficiência de Vitamina D/complicações
Deficiência de Vitamina D/tratamento farmacológico
Vitaminas/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antimanic Agents); 0 (Parathyroid Hormone); 0 (Sodium Chloride Symporter Inhibitors); 0 (Vitamins); 1406-16-2 (Vitamin D); 9FN79X2M3F (Lithium); SQE6VB453K (Calcium Gluconate); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170815
[St] Status:MEDLINE


  6 / 12167 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28774260
[Au] Autor:Guarnieri V; Seaberg RM; Kelly C; Jean Davidson M; Raphael S; Shuen AY; Baorda F; Palumbo O; Scillitani A; Hendy GN; Cole DEC
[Ad] Endereço:Medical Genetics, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy. v.guarnieri@operapadrepio.it.
[Ti] Título:Large intragenic deletion of CDC73 (exons 4-10) in a three-generation hyperparathyroidism-jaw tumor (HPT-JT) syndrome family.
[So] Source:BMC Med Genet;18(1):83, 2017 Aug 03.
[Is] ISSN:1471-2350
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Inactivating mutations of CDC73 cause Hyperparathyroidism-Jaw Tumour syndrome (HPT-JT), Familial Isolated Hyperparathyroidism (FIHP) and sporadic parathyroid carcinoma. We conducted CDC73 mutation analysis in an HPT-JT family and confirm carrier status of the proband's daughter. METHODS: The proband had primary hyperparathyroidism (parathyroid carcinoma) and uterine leiomyomata. Her father and daughter had hyperparathyroidism (parathyroid adenoma) but no other manifestations of HPT-JT. CDC73 mutation analysis (sequencing of all 17 exons) and whole-genome copy number variation (CNV) analysis was done on leukocyte DNA of the three affecteds as well as the proband's unaffected sister. RESULTS: A novel deletion of exons 4 to 10 of CDC73 was detected by CNV analysis in the three affecteds. A novel insertion in the 5'UTR (c.-4_-11insG) that co-segregated with the deletion was identified. By in vitro assay the 5'UTR insertion was shown to significantly impair the expression of the parafibromin protein. Screening for the mutated CDC73 confirmed carrier status in the proband's daughter and the biochemistry and ultrasonography led to pre-emptive surgery and resolution of the hyperparathyroidism. CONCLUSIONS: A novel gross deletion mutation in CDC73 was identified in a three-generation HPT-JT family emphasizing the importance of including screening for large deletions in the molecular diagnostic protocol.
[Mh] Termos MeSH primário: Adenoma/genética
Fibroma/genética
Hiperparatireoidismo/genética
Neoplasias Maxilomandibulares/genética
Deleção de Sequência
Proteínas Supressoras de Tumor/genética
[Mh] Termos MeSH secundário: Regiões 5' não Traduzidas
Adenoma/patologia
Adolescente
Adulto
Alelos
Animais
Sequência de Bases
Criança
DNA/química
DNA/isolamento & purificação
DNA/metabolismo
Variações do Número de Cópias de DNA
Éxons
Feminino
Fibroma/patologia
Testes Genéticos
Células HEK293
Seres Humanos
Hiperparatireoidismo/patologia
Neoplasias Maxilomandibulares/patologia
Leucócitos/metabolismo
Masculino
Meia-Idade
Linhagem
Alinhamento de Sequência
Proteínas Supressoras de Tumor/metabolismo
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (5' Untranslated Regions); 0 (CDC73 protein, human); 0 (Tumor Suppressor Proteins); 9007-49-2 (DNA)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170917
[Lr] Data última revisão:
170917
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170805
[St] Status:MEDLINE
[do] DOI:10.1186/s12881-017-0445-0


  7 / 12167 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28658490
[Au] Autor:Stephen AE; Mannstadt M; Hodin RA
[Ad] Endereço:Department of Surgery, Massachusetts General Hospital, Boston.
[Ti] Título:Indications for Surgical Management of Hyperparathyroidism: A Review.
[So] Source:JAMA Surg;152(9):878-882, 2017 Sep 01.
[Is] ISSN:2168-6262
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Importance: Primary hyperparathyroidism (pHPT) is a common clinical entity, with approximately 100 000 new cases diagnosed each year in the United States. Most patients with pHPT have a relatively mild form of the disease and present with few if any overt signs or symptoms. This has led to a dilemma regarding which patients should be considered for parathyroid surgery. In this article, we review the established literature on the indications for surgery in asymptomatic pHPT and discuss the most recent consensus conference guidelines. Observations: The reviewed literature suggests that there were improved outcomes among patients with asymptomatic pHPT who underwent curative surgery. Conclusions and Relevance: Most patients with pHPT should be considered for parathyroidectomy. More randomized clinical trials are needed to strongly support a surgical recommendation for all asymptomatic patients with pHPT.
[Mh] Termos MeSH primário: Hiperparatireoidismo/cirurgia
Paratireoidectomia/métodos
[Mh] Termos MeSH secundário: Seres Humanos
Avaliação de Resultados (Cuidados de Saúde)
Seleção de Pacientes
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171002
[Lr] Data última revisão:
171002
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170629
[St] Status:MEDLINE
[do] DOI:10.1001/jamasurg.2017.1721


  8 / 12167 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28614027
[Au] Autor:Sethi N; England RJA
[Ad] Endereço:Specialist Registrar, Department of Otorhinolaryngology-Head and Neck Surgery, Hull Teaching Hospitals NHS Trust, Castle Hill Hospital, Cottingham, East Yorkshire.
[Ti] Título:Parathyroid surgery: from inception to the modern day.
[So] Source:Br J Hosp Med (Lond);78(6):333-337, 2017 Jun 02.
[Is] ISSN:1750-8460
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Parathyroid surgery has undergone great changes since its inception less than a century ago. It is still the only definitive option available to cure primary or tertiary hyperparathyroidism. This review details the development of parathyroid surgery, our understanding of hyperparathyroidism and the treatment options available. It also discusses the technological advances that have enabled parathyroid localization and prediction of surgical success.
[Mh] Termos MeSH primário: Adenoma/história
Hiperparatireoidismo/história
Glândulas Paratireoides/cirurgia
Neoplasias das Paratireoides/história
Paratireoidectomia/história
[Mh] Termos MeSH secundário: Adenoma/cirurgia
História do Século XIX
História do Século XX
História do Século XXI
Seres Humanos
Hiperparatireoidismo/cirurgia
Neoplasias das Paratireoides/cirurgia
[Pt] Tipo de publicação:HISTORICAL ARTICLE; JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170829
[Lr] Data última revisão:
170829
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170615
[St] Status:MEDLINE
[do] DOI:10.12968/hmed.2017.78.6.333


  9 / 12167 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28539166
[Au] Autor:Wilczek ML; Kälvesten J; Bergström I; Pernow Y; Sääf M; Freyschuss B; Brismar TB
[Ad] Endereço:Division of Radiology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. Electronic address: michael.wilczek@gmail.com.
[Ti] Título:Can secondary osteoporosis be identified when screening for osteoporosis with digital X-ray radiogrammetry? Initial results from the Stockholm Osteoporosis Project (STOP).
[So] Source:Maturitas;101:31-36, 2017 Jul.
[Is] ISSN:1873-4111
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To identify causes of low age-adjusted bone mass at digital X-ray radiogrammetry (DXR) in individuals attending an osteoporosis screening program. STUDY DESIGN: In a descriptive observational cohort study, women aged 40-75 years who attended a general mammography screening program had their bone mass investigated with DXR and answered a questionnaire regarding several clinical risk factors for osteoporosis. Each month the 2% with the lowest Z-scores were selected for further clinical examination with DXA of the hip and lumbar spine and pre-defined blood tests. MAIN OUTCOME MEASURE: Causes of secondary osteoporosis determined by clinical and laboratory evaluation. RESULTS: 14,783 women attended mammography screening and had their bone mass evaluated. In total, 327 women had a low DXR BMD and 281 accepted further DXA examination. Of these, 93 (33.1%) had osteoporosis. The diagnosis was new in 79 cases (84.9%) and in 32 (34.4%) a potential underlying cause was identified. Primary hyperparathyroidism was found in 8.6% and secondary hyperparathyroidism in 13.5%. Several self-reported risk factors for osteoporosis, including rheumatic disease, insulin-treated diabetes, cortisone treatment, smoking, reduced mobility, hyperparathyroidism, and malabsorption, were significantly more common among those selected for DXA referral than in the total cohort. For example, rheumatic disease and insulin-treated diabetes were reported 3.4 and 2.3 times as often, respectively. CONCLUSION: The prevailing potential cause of secondary osteoporosis according to DXR was primary and secondary hyperparathyroidism. Most of the women with these conditions were previously undiagnosed, indicating that further follow-up of patients with low age-adjusted DXR BMD is justified.
[Mh] Termos MeSH primário: Osteoporose/diagnóstico por imagem
[Mh] Termos MeSH secundário: Adulto
Idoso
Densidade Óssea
Estudos de Coortes
Feminino
Quadril/diagnóstico por imagem
Seres Humanos
Hiperparatireoidismo/complicações
Hiperparatireoidismo/diagnóstico por imagem
Vértebras Lombares/diagnóstico por imagem
Mamografia
Programas de Rastreamento
Meia-Idade
Osteoporose/diagnóstico
Osteoporose/etiologia
Intensificação de Imagem Radiográfica
Fatores de Risco
Raios X
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171108
[Lr] Data última revisão:
171108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170526
[St] Status:MEDLINE


  10 / 12167 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28535228
[Au] Autor:Hai MTT; Guettier JM; Rosebraugh CJ
[Ad] Endereço:Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
[Ti] Título:Dosing of Etelcalcetide and Cinacalcet for Secondary Hyperparathyroidism.
[So] Source:JAMA;317(20):2132, 2017 05 23.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Cloridrato de Cinacalcete
Hiperparatireoidismo Secundário
[Mh] Termos MeSH secundário: Cálcio
Seres Humanos
Hiperparatireoidismo
Hormônio Paratireóideo
Diálise Renal
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Parathyroid Hormone); 1K860WSG25 (Cinacalcet Hydrochloride); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170606
[Lr] Data última revisão:
170606
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170524
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.4743



página 1 de 1217 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde